AR083338A1 - Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r) - Google Patents
Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r)Info
- Publication number
- AR083338A1 AR083338A1 ARP110103663A AR083338A1 AR 083338 A1 AR083338 A1 AR 083338A1 AR P110103663 A ARP110103663 A AR P110103663A AR 083338 A1 AR083338 A1 AR 083338A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- pharmaceutical formulation
- liquid pharmaceutical
- buffer
- concentration
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39028310P | 2010-10-06 | 2010-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083338A1 true AR083338A1 (es) | 2013-02-21 |
Family
ID=45995014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103663 AR083338A1 (es) | 2010-10-06 | 2011-10-03 | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r) |
Country Status (13)
| Country | Link |
|---|---|
| AR (1) | AR083338A1 (sr) |
| DK (2) | DK3354280T3 (sr) |
| ES (2) | ES2820246T3 (sr) |
| HK (1) | HK1258305A1 (sr) |
| HR (1) | HRP20181822T1 (sr) |
| HU (1) | HUE052089T2 (sr) |
| LT (1) | LT2624865T (sr) |
| PT (1) | PT3354280T (sr) |
| RS (1) | RS57850B1 (sr) |
| SI (1) | SI2624865T1 (sr) |
| TW (7) | TWI718890B (sr) |
| UA (1) | UA111731C2 (sr) |
| UY (1) | UY33652A (sr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3470432T3 (pl) | 2012-08-21 | 2022-02-07 | Sanofi Biotechnology | Sposoby leczenia lub zapobiegania astmie przez podawanie antagonisty IL-4R |
| EP3010539B1 (en) * | 2013-06-21 | 2019-07-24 | Sanofi Biotechnology | Methods for treating nasal polyposis by administering an il-4r antagonist |
| NZ631118A (en) * | 2013-06-21 | 2019-05-31 | Regeneron Pharma | Methods for treating nasal polyposis by administering an il-4r antagonist |
| CA2967602A1 (en) | 2014-11-14 | 2016-05-19 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| HUE064655T2 (hu) | 2017-10-30 | 2024-04-28 | Sanofi Biotechnology | IL-4R antagonista asztma kezelésére vagy megelõzésére szolgáló eljárásban |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| ES2332082B1 (es) * | 2008-07-24 | 2010-10-26 | Consejo Superior De Investigaciones Cientificas (Csic) 45% | Sistema de alineacion de patrones en un sustrato mediante litografia por estencil. |
| EP2327831B1 (en) * | 2008-09-10 | 2014-01-22 | Japan Exlan Company Limited | A cross-linked acrylate fiber and a method for manufacturing it |
| US8318161B2 (en) * | 2009-03-06 | 2012-11-27 | Genentech, Inc. | Anti-oxidized LDL antibody formulation |
-
2011
- 2011-05-10 UA UAA201305598A patent/UA111731C2/uk unknown
- 2011-10-03 AR ARP110103663 patent/AR083338A1/es not_active Application Discontinuation
- 2011-10-05 ES ES18161288T patent/ES2820246T3/es active Active
- 2011-10-05 ES ES11770625.9T patent/ES2687813T3/es active Active
- 2011-10-05 TW TW109107375A patent/TWI718890B/zh active
- 2011-10-05 TW TW109131629A patent/TWI782325B/zh active
- 2011-10-05 TW TW108111631A patent/TWI690329B/zh active
- 2011-10-05 LT LTEP11770625.9T patent/LT2624865T/lt unknown
- 2011-10-05 RS RS20181308A patent/RS57850B1/sr unknown
- 2011-10-05 DK DK18161288.8T patent/DK3354280T3/da active
- 2011-10-05 TW TW100135992A patent/TWI498121B/zh active
- 2011-10-05 TW TW104123984A patent/TWI568445B/zh active
- 2011-10-05 TW TW105134483A patent/TWI679988B/zh active
- 2011-10-05 TW TW111138434A patent/TW202320851A/zh unknown
- 2011-10-05 HU HUE18161288A patent/HUE052089T2/hu unknown
- 2011-10-05 PT PT181612888T patent/PT3354280T/pt unknown
- 2011-10-05 DK DK11770625.9T patent/DK2624865T3/en active
- 2011-10-05 SI SI201131568T patent/SI2624865T1/sl unknown
- 2011-10-06 UY UY33652A patent/UY33652A/es unknown
-
2018
- 2018-10-31 HR HRP20181822TT patent/HRP20181822T1/hr unknown
-
2019
- 2019-01-15 HK HK19100671.5A patent/HK1258305A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE052089T2 (hu) | 2021-04-28 |
| UA111731C2 (uk) | 2016-06-10 |
| RS57850B1 (sr) | 2018-12-31 |
| TW201221141A (en) | 2012-06-01 |
| TWI782325B (zh) | 2022-11-01 |
| DK2624865T3 (en) | 2018-10-22 |
| DK3354280T3 (da) | 2020-09-28 |
| SI2624865T1 (sl) | 2018-10-30 |
| TW201716086A (zh) | 2017-05-16 |
| LT2624865T (lt) | 2018-10-25 |
| TWI690329B (zh) | 2020-04-11 |
| TW202320851A (zh) | 2023-06-01 |
| TWI568445B (zh) | 2017-02-01 |
| UY33652A (es) | 2012-04-30 |
| TWI498121B (zh) | 2015-09-01 |
| TW202102262A (zh) | 2021-01-16 |
| ES2820246T3 (es) | 2021-04-20 |
| ES2687813T3 (es) | 2018-10-29 |
| TW202026011A (zh) | 2020-07-16 |
| PT3354280T (pt) | 2020-09-01 |
| HRP20181822T1 (hr) | 2018-12-28 |
| TWI679988B (zh) | 2019-12-21 |
| HK1258305A1 (zh) | 2019-11-08 |
| TWI718890B (zh) | 2021-02-11 |
| TW201924718A (zh) | 2019-07-01 |
| TW201542229A (zh) | 2015-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR089787A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ang2 | |
| JP2013543505A5 (sr) | ||
| FI3606504T3 (fi) | Stabiili vasta-aineformulaatio | |
| PE20170948A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r) | |
| AR082171A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ngf | |
| HRP20201268T1 (hr) | Stabilne formulacije koje sadrže anti-pcsk9 antitijela | |
| NZ730821A (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
| AR075715A1 (es) | Formulacion de anticuerpo liofilizado | |
| RU2019100221A (ru) | Составы на основе антитела к CD19 | |
| AR083338A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r) | |
| PE20081610A1 (es) | Formulaciones de anticuerpos anti-il-13 y usos de los mismos | |
| FI2687202T3 (fi) | Ihonalainen anti-HER2-vasta-aineformulaatio | |
| RU2017107847A (ru) | Стабильный состав на основе антитела к il-4r-альфа | |
| AR079746A1 (es) | Formulacion farmaceutica de anticuerpo | |
| EA201200475A1 (ru) | Высококонцентрированные фармацевтические композиции, содержащие антитело к cd20 | |
| PE20061043A1 (es) | Composicion farmaceutica que comprende anticuerpos monoclonales | |
| PE20141413A1 (es) | Formulaciones de anticuerpo y metodos | |
| HRP20120903T1 (hr) | Tekuä†a formulacija koja sadrži visoku koncentraciju protutijela | |
| AR109494A1 (es) | Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos | |
| DOP2009000222A (es) | Formulaciones estables de anticuerpo | |
| NZ630885A (en) | Antibody formulation | |
| PE20141159A1 (es) | Metodos para tratar o prevenir trastornos relacionados con el colesterol | |
| PE20060879A1 (es) | Formulacion anticuerpo anti a beta | |
| AR099084A2 (es) | Composiciones de anticuerpos anti-ctla-4 | |
| CL2021001587A1 (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |